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disease prevention in Australia: a modelling study
Linda J Cobiac1*, Anne Magnus2, Jan J Barendregt1, Rob Carter2 and Theo Vos1Abstract
Background: Cardiovascular disease is the leading cause of death worldwide. Like many countries, Australia is
currently changing its guidelines for cardiovascular disease prevention from drug treatment for everyone with ‘high
blood pressure’ or ‘high cholesterol’, to prevention based on a patient’s absolute risk. In this research, we model
cost-effectiveness of cardiovascular disease prevention with blood pressure and lipid drugs in Australia under three
different scenarios: (1) the true current practice in Australia; (2) prevention as intended under the current guidelines;
and (3) prevention according to proposed absolute risk levels. We consider the implications of changing to absolute
risk-based cardiovascular disease prevention, for the health of the Australian people and for Government health
sector expenditure over the long term.
Methods: We evaluate cost-effectiveness of statins, diuretics, ACE inhibitors, calcium channel blockers and
beta-blockers, for Australian men and women, aged 35 to 84 years, who have never experienced a heart
disease or stroke event. Epidemiological changes and health care costs are simulated by age and sex in a
discrete time Markov model, to determine total impacts on population health and health sector costs over
the lifetime, from which we derive cost-effectiveness ratios in 2008 Australian dollars per quality-adjusted life
year.
Results: Cardiovascular disease prevention based on absolute risk is more cost-effective than prevention
under the current guidelines based on single risk factor thresholds, and is more cost-effective than the
current practice, which does not follow current clinical guidelines. Recommending blood pressure-lowering
drugs to everyone with at least 5% absolute risk and statin drugs to everyone with at least 10% absolute risk,
can achieve current levels of population health, while saving $5.4 billion for the Australian Government over
the lifetime of the population. But savings could be as high as $7.1 billion if Australia could match the
cheaper price of statin drugs in New Zealand.
Conclusions: Changing to absolute risk-based cardiovascular disease prevention is highly recommended for
reducing health sector spending, but the Australian Government must also consider measures to reduce the
cost of statin drugs, over and above the legislated price cuts of November 2010.Background
Cardiovascular disease is a leading cause of death and ill
health in Australia [1]. Despite many decades in decline,
with less smoking and more successful treatment, cardio-
vascular disease remains the number one cost to the Aus-
tralian health sector [2], and its prevention has been
declared a national priority [3,4].* Correspondence: l.cobiac@uq.edu.au
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reproduction in any medium, provided the orPharmaceuticals can be used to prevent ischaemic
heart disease and stroke events by treating unhealthy
blood pressure and lipid levels [5,6]. Around 10% to 20%
of Australians without cardiovascular disease already re-
port taking these preventive therapies, with at least half
taking more than one drug [7,8]. However, some of these
drugs, such as statins, are very expensive, and with rap-
idly increasing costs of the Pharmaceutical Benefits
Scheme (PBS), it is imperative that we are identifying
and providing drug treatment to those most at risk of
going on to develop cardiovascular disease.Ltd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
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currently based on a confusing mix of rules and prescrib-
ing criteria for defining risk factor thresholds for ‘high
blood pressure’ or ‘high cholesterol’ [9-12].A synthesis of current guidelines and prescribing
criteria for prevention of cardiovascular disease in
Australia
Criteria for treatment of blood pressure:
 Blood pressure > 140/90 mmHg
 Blood pressure > 130/80 mmHg and diabetes
Criteria for treatment of lipids:
 Diabetes and age > 60 years
 Diabetes and total cholesterol > 5.5 mmol/L
 Total cholesterol > 6.5 mmol/L and HDL
cholesterol < 1 mmol/L
 Total cholesterol > 6.5 mmol/L and hypertension
 Total cholesterol > 5.5 mmol/L and HDL
cholesterol < 1 mmol/L and hypertension
 Total cholesterol > 7.5 mmol/L or triglycerides > 4
mmol/L for men aged 35-75 years or post-
menopausal women < 75 years
 Total cholesterol > 9 mmol/L or triglycerides > 8
mmol/L
However, in other countries such as New Zealand
and the United Kingdom, recommended practice has
progressed to screening and treatment based on a
patient’s absolute risk [13], which takes additional risk
factors, such as age, sex, smoking and diabetes, into
account, alongside blood pressure and lipid levels.
This is a more effective and cost-effective approach to
cardiovascular disease prevention [14], and similar
changes have been proposed for guidelines in Austra-
lia [15].
In this research, we model cost-effectiveness of car-
diovascular disease prevention with blood pressure
and lipid drugs in Australia under three different sce-
narios: (1) the actual current practice in Australia
(based on self-reported use of blood pressure drugs,
lipid drugs or both, in a national survey); (2) preven-
tion as intended under the current guidelines (based
on applying current risk factor threshold rules to sur-
vey participants’ measures of blood pressure and chol-
esterol); and (3) prevention according to proposed
absolute risk levels (based on applying an Australian
absolute risk prediction equation to survey partici-
pants’ age, sex, blood pressure levels, cholesterol
levels, smoking status and diabetes status) . We con-
sider the implications of changing to absolute risk-
based cardiovascular disease prevention, for the health
of the Australian people and for Government health
sector expenditure over the long term.Methods
Screening
We model cost-effectiveness of cardiovascular disease pre-
vention in the 2008 Australian population aged 35 years
and older [16]. The proportion of Australians currently
taking blood pressure and lipid drugs (‘current practice’) is
determined from self-reported use of cardiovascular dis-
ease drugs in those who have never experienced an
ischaemic heart disease or stroke event in the 1999–2000
AusDiab dataset [7].
Since primary prevention screening occurs primarily in
general practice in Australia, we determine the number of
Australians who would be screened for cardiovascular dis-
ease risk from rates of general practice attendance in
BEACH data [17] and estimates of general practitioner
(GP) participation in risk assessment based on participa-
tion in Practice Incentive Programs. Eligibility for prevent-
ive drugs under the current mix of single risk factor-based
guidelines and prescribing criteria is determined by the cri-
teria defined in the synthesis of current guidelines and pre-
scribing criteria for prevention of cardiovascular disease in
Australia. Eligibility according to absolute risk is derived
using the Framingham risk prediction equation [18].
Guidelines around measuring absolute risk in Australia
[15] and New Zealand [19] are based on the 1991 version
of the Framingham equation, which predicts the probabil-
ity of a fatal or non-fatal ischaemic heart disease or stroke
event in the next five years (in contrast to the ten-year pre-
diction equation used in UK and European guidelines
[13]). It is not possible to translate directly between the
five and ten year predictions, because the risk of an event
will increase with age, but as a rough rule-of-thumb we
can say that a 5% five-year risk is approximately equivalent
to a 10% ten-year risk and a 10% five-year risk is approxi-
mately equivalent to a 20% ten-year risk.
The Framingham risk is determined using the Aus-
Diab data set for 1999–2000 [7]. Probability of an
event in the next five years is derived from data on
the age, sex, smoking status, total cholesterol level,
high density lipoprotein cholesterol level and diabetes
status of AusDiab participants who report never hav-
ing experienced an ischaemic heart disease or stroke
event. For participants reporting current use of blood
pressure or lipid drugs, we assume a mean blood
pressure-lowering effect of 9.1 mmHg (systolic) and
5.5 mmHg (diastolic), and a mean statin therapy effect
of 17.1% reduction in total cholesterol, 25.6% reduc-
tion in low density lipoprotein cholesterol, 9.3% re-
duction in triglyceride and 3.3% increase in high
density lipoprotein [5,6]. The Framingham risk predic-
tion is then calibrated for the Australian population
from the Framingham risk distribution in the
AusDiab population who do not have IHD or stroke,
and known Australian incidence of IHD and stroke
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ease prevention for three levels of risk, defined by the
probability of a cardiovascular disease event in the next
five years: ≥15% risk, ≥10% risk and ≥5% risk.
Treatment
We evaluate cost-effectiveness for primary prevention with
a combination of statin and blood pressure-lowering drugs
(diuretics, ACE inhibitors, calcium channel blockers and
beta-blockers). Current combinations of blood-pressure
lowering drugs are derived from current usage patterns in
the Avoid Stroke as Soon as Possible (ASAP) study [8]. For
primary prevention according to the existing guidelines
and absolute risk, we assume that blood pressure-lowering
agents are prescribed in the most cost-effective order, with
prescription of one, two or (at most) three blood pressure-
lowering drugs based on the ASAP study data.
Reductions in risk of ischaemic heart disease and stroke
associated with drug use are based on meta-analyses of
primary prevention trials [5,6], with the effect of multiple
drugs determined multiplicatively [20]. We use measures
of statin drug efficacy for men and women combined, but
also evaluate results with different measures of drug effi-
cacy for men and women, based on the meta-analyses of
trials that reported results by gender.
There is limited data on long-term adherence to blood
pressure and statin drugs in primary prevention. We as-
sume that 40% of patients will discontinue treatment at
12 months based on Australian data on discontinuation
of statins [21] and blood pressure-lowering drugs [22].
Remaining patients are assumed to adhere to treatment
long term, with twice-yearly visits to their general practi-
tioner (GP). We do not include any additional costs (or
effects) of intervention to improve or maintain adher-
ence, such as patient education programs and reminders.
The unit costs of treatment are derived from
Pharmaceutical Benefits Scheme (PBS) [23] data on
scripts/services and benefits paid (taking the mix of ‘gen-
eral’, ‘concession’, ‘safety net’ and ‘non-safety-net’ patients
into account) and Medicare Benefits Schedule (MBS) costs
for associated general practitioner visits and blood tests
(Table 1 and Table 2). Where more than one brand or dose
of drug is available, an average annual cost is determined
from the 2008 PBS mix of scripts provided and the equiva-
lent standard dose of the blood pressure-lowering [24] and
statin drugs [25]. For comparison, we also consider results
when statin drugs are costed at the cheaper price of statin
drugs in nearby New Zealand.
Costs are calculated in the model according to how
many patients receive blood pressure drugs only, how
many receive lipid drugs only and how many receive
both blood pressure and lipid drugs. With single risk
factor screening, some patients will receive blood
pressure or lipid drugs only, while some will receiveboth. With absolute risk screening, however, all eli-
gible patients receive a combination of both blood
pressure and lipid drugs. We assume that all patients
receiving treatment, no matter how they are screened,
will have one long visit (at least 20 minutes) with
their GP and one blood test (e.g. to determine lipid
levels) in the first year of treatment. All patients are
then assumed to have two short visits (up to 20 min-
utes) with their GP and two blood tests annually
thereafter, for on-going monitoring and repeat drug
prescription. Patients receiving blood pressure-lower-
ing drugs (e.g. ACE inhibitors) also receive two add-
itional blood tests and two short GP visits in the first
year of treatment, for monitoring of urea and electro-
lyte levels.Cost-effectiveness modelling
In a discrete time Markov model, we simulate IHD
and stroke events, by age and sex, over the lifetime of
the Australian population without a history of
cardiovascular disease in 2008, from age 35 years. The
Markov model has four primary health states, with
transition rates capturing probabilities of incidence
and case fatality for fatal and non-fatal IHD and
stroke events. Rates are derived from Australian
hospital and mortality databases [26,27], the Perth
MONICA study [28] and the NEMESIS [29] study.
Trends are incorporated to capture underlying
changes in IHD and stroke incidence and case fatality
over time [30]. A full description of the model and
data inputs is provided in the Additional File 1.
Prevention of cardiovascular disease under the three
scenarios (actual current practice; prevention as intended
under the current single risk factor-based guidelines; and
prevention according to proposed absolute risk-based
guidelines) is evaluated in comparison to no intervention
for prevention of cardiovascular disease. Incidence of is-
chaemic heart disease and stroke under the comparator
conditions of no intervention, are back-calculated using
estimates of relative risks (from Table 3), the proportion
of the population without cardiovascular disease who are
taking preventive cardiovascular drugs as recorded in
AusDiab [7] and BEACH general practice data [31,32].
Using the Markov model, we simulate the difference
between total years of life that would be lived by the
population receiving preventive drug intervention
under the three scenarios (taking uptake and adher-
ence into account), and total years of life that would
be lived if the same population did not receive any
drugs for cardiovascular disease prevention. To cap-
ture the impact on morbidity, we adjust the years of
life that are lived (in both intervention and compara-
tor populations) using utility weights that capture the
Table 1 Costs of GP visits and blood tests for lipid and blood pressure-lowering therapy
Unit price (2008A$) Number of units Sources and assumptions
Government Patient Year 1 Year 2+
Medical costs with lipid treatment*
Long GP visit $54.19 $9.56 1 − MBS cost of Level C consultation [33]
Short GP visit $28.52 $5.03 − 2 MBS cost Level B consultation [33]
Blood test – lipids $15.13 $2.67 1 2 MBS cost for up to 6 test items (MBS Item 66512) [33]
Medical costs with blood pressure treatment*
Long GP visit $54.19 $9.56 1 − MBS cost of Level C consultation [33]
Short GP visit $28.52 $5.03 2 2 MBS cost Level B consultation [33]
Blood test – urea, electrolytes $15.13 $2.67 3 2 MBS cost for up to 6 test items (MBS Item 66512) [33]
Medical costs with lipid and blood pressure treatment**
Long GP visit $54.19 $9.56 1 − MBS cost of Level C consultation [33]
Short GP visit $28.52 $5.03 2 2 MBS cost Level B consultation [33]
Blood test – lipids, urea, electrolytes $15.13 $2.67 4 2 MBS cost for up to 6 test items (MBS Item 66512) [33]
* Patients eligible according to single risk factor thresholds.
** Patients eligible according to single risk factor thresholds or eligible according to absolute risk.
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[34]. Time lived with heart disease or stroke is also
weighted to reflect the associated health loss [35-37].
We simulate the impact of each scenario on costs
of treating ischaemic heart disease and stroke over
the lifetime of the population. Costs of treating is-
chaemic heart disease in the first year of illness areTable 2 Costs of lipid and blood pressure-lowering pharmace
Unit price (2008A$) Number of unit
Government Patient Year 1 Year 2
Pharmaceutical costs
Annual cost of low-dose
diuretic therapy
$52.03 $18.79 1 1
Annual cost of calcium channel
blocker therapy
$163.66 $54.22 1 1
Annual cost of ACE inhibit
or therapy
$130.85 $81.21 1 1
Annual cost of beta-blocker
therapy
$169.59 $47.09 1 1
Annual cost of statin
therapy
$508.64 $178.79 1 1
Annual cost of statin therapy in
New Zealand
$18.25 − 1 1
Annual cost of current practice
lipid-lowering therapy
$559.68 $123.37 1 1
Annual cost of current practice
blood pressure-lowering therapy
$169.59 $47.09 1 1
NB. All costs adjusted to 2008 Australian dollars using Australian health price deflato
relevant.derived from a Victorian Government study [42] of
hospital inpatient costs for ischaemic heart disease
treatment and rehabilitation admissions, and from a
study by Lim [43] of government and patient out-of-
hospital costs for consultations, drugs and diagnostic
procedures, and Medicare rebates for private-sector
consultations and procedures. Costs of treating strokeuticals
s Sources and assumptions
+
Average annual PBS cost for the standard daily dose [24] of
hydrochlorothiazide, chlorthalidone and indapamide,
weighted by scripts provided in 2008 [23].
Average annual PBS cost for the standard daily dose [24] of
verapimil, amlodopine (maleate), nifedipine, felodipine,
amlodopine (besylate) and lercanidipine,weighted by scripts provided
in 2008 [23].
Average annual PBS cost for the standard daily dose [24] of
captopril, fosinopril, enalopril, ramipril, quinapril, lisinopril,
trandolopril and perindopril, weighted by scripts provided in
2008 [23].
Average annual PBS cost for the standard daily dose [25]
of fluvastatin, simvastatin, atorvastatin, pravastatin and
rosuvastatin, weighted by scripts provided in 2008 [23].
Average annual PBS cost for the standard daily dose [25]
of fluvastatin, simvastatin, atorvastatin, pravastatin and rosuvastatin,
weighted by scripts provided in 2008 [23].
Average annual cost of simvastatin (40 mg/day) in New Zealand [38].
Average annual cost from actual PBS expenditure on
lipid-lowering drugs in 2008 [23].
Average annual cost from actual PBS expenditure on blood
pressure-lowering drugs in 2008 [23]. Mix of diuretics, beta-blockers,
calcium channel blockers and ACE inhibitors based on BEACH
general practice data [32].
rs [39], consumer price index [40] and/or purchasing power parities [41] where
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of treatment in subsequent years are derived from the
NEMESIS study of stroke costs [44].
Total costs of intervention (to Government and
patients), treatment costs that could be averted and over-
all population health impacts (measured in quality
adjusted life years) are determined by simulating the
population over time until everyone is dead or has
reached 100 years of age. All future costs and health out-
comes are discounted back to the baseline year at a rate
of 3% [45]. We take the difference in cost of intervention
to Government, between each scenario and current prac-
tice, to reflect the potential cost-savings in blood pres-
sure and statin drug prescribing.
We derive 95% uncertainty intervals for all cost and
health outcome measures from uncertainty around input
parameters (Table 3) by multivariate probabilistic sensitivity
analysis [46] using the Excel Add-In program @Risk
(Palisade, Version 4.5). Finally, cost-effectiveness ratios areTable 3 Model input parameters and their uncertainty distrib
Parameter Value
Mean (SE or 95%CI)
Uncer
RR of IHD with treatment
-Statin
-Diuretic
-Calcium channel blocker
-ACE inhibitor
-Beta-blocker
0.70 (0.61 to 0.81)
0.86 (0.75 to 0.98)
0.85 (0.78 to 0.92)
0.83 (0.78 to 0.89)
0.78 (0.89 to 1.02)
RR of stroke with treatment
-Statin
-Diuretic
-Calcium channel blocker
-ACE inhibitor
-Beta-blocker
0.81 (0.71 to 0.93)
0.62 (0.53 to 0.72)
0.66 (0.58 to 0.75)
0.78 (0.66 to 0.92)
0.70 (0.83 to 0.99)
RR of stroke in IHD
-Men
-Women
1.32 (0.20)
1.88 (0.30)
RR of IHD in stroke
-Men
-Women
2.64 (0.07)
2.85 (0.04)
IHD treatment cost
-First year
-Subsequent years
$12,921
$4,539
Stroke treatment cost
-First year
-Subsequent years
$23,581
$3,201
Proportion of population
visiting a GP in one year
35–44 yrs
45–54 yrs
55–64 yrs
65–74 yrs
75+ yrs
Men Women
73% 88%
81% 89%
81% 89%
93% 94%
99% 99%
Proportion of GPs measuring
absolute risk
65% (6.5%)
First year drug discontinuation
rate
40% (8%)
NB. All costs adjusted to 2008 Australian dollars using Australian health price deflatoevaluated in Australian dollars per quality adjusted life year
(QALY) for the year 2008, and compared with a value-
for-money threshold of $50,000/QALY [51].
Results
Current cardiovascular disease prevention does not
follow the existing mix of guidelines; 1.2 million
Australians are missing out on treatment for which
they are currently eligible and another 1.2 million are
receiving treatment even though they are not cur-
rently eligible (Figure 1a). Most of those missing out
on treatment under current guidelines are less than
65 years of age. A change to cardiovascular disease
prevention based on absolute risk, however, would
lead to an increase in average age of those eligible for
treatment. If cardiovascular disease prevention is
recommended for everyone with at least 5% absolute
risk (Figure 1b) 2.3 million Australians will be eligible
for treatment, of whom 1.1 million are alreadyutions
tainty distribution Sources and assumptions
Normal
(lnRR)
Meta-analyses of primary prevention
trials [5,6,47]
Normal
(lnRR)
Meta-analyses of primary prevention
trials [5,6,47]
Normal
(lnRR)
Busselton study [48,49]
Normal
(lnRR)
Busselton study [48,49]
Uniform Lim [43]. Uniform distribution assumed
to vary by ±25% around mean.
Uniform Lim [43]. Uniform distribution assumed
to vary by ±25% around mean.
– BEACH data [17]
Beta Practice Incentives Program data [50].
Beta Estimate from Australian survey data [21,22].
Standard error assumed to be 20% of point
estimate.
rs [39]. RR – relative risk.
Figure 1 Change in eligibility for treatment with preventive drugs. The number of Australians already receiving treatment, newly eligible for
treatment or no longer eligible for treatment, based on: (a) the existing single risk factor-based guidelines; and (b) the proposed absolute risk-
based guidelines (≥5% cardiovascular disease risk).
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million Australians currently taking preventive drugs,
mostly aged under 65 years, will no longer be eligible
for treatment.
A change in guidelines will not lead to an improve-
ment in population health overall, but current levels
of population health could be achieved at a much
lower cost. Cardiovascular disease prevention based
on absolute risk is more cost-effective than prevention
under the current guidelines, which are based on sin-
gle risk factor thresholds, and more cost-effective than
the current practice (Figure 2). Recommending bloodpressure-lowering drugs to everyone with at least 5%
absolute risk and statin drugs to everyone with at
least 10% absolute risk, can achieve current levels of
population health, while saving $5.4 billion for the
Government over the lifetime of the population
(Table 4). If Australia could match the cheaper price
of statins in New Zealand, however, Government cost
savings could be as high as $7.1 billion over the life-
time of the population ($93 million in the first year).
Additional analysis with separate measures of drug effi-
cacy for men and women did not significantly alter cost-
effectiveness (Additional File 2).
Figure 2 Cost-effectiveness of cardiovascular disease prevention. Graph shows cost-effectiveness of current practice, cost-effectiveness of
existing single risk factor-based guidelines, and cost-effectiveness of prevention targeted at ≥15%, ≥10% and ≥5% absolute risk groups (NB. The
scatter of points for each intervention reflects the uncertainty in the cost-effectiveness result. All points that fall under the threshold line, which is
illustrated here at $50,000/QALY, are considered ‘cost-effective’).
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Changing from single risk factor thresholds as a basis for
primary prevention of cardiovascular disease to an abso-
lute risk approach is highly recommended. There is po-
tential for substantial reductions in health sectorTable 4 Lifetime costs, health gain and cost-effectiveness of c
Lifetime health gain
(QALYs)
Lifetime intervent
costs to Governm
($billion)
Current practice 270,000 (220,000 to 310,000) $12 ($12 to $12)
Existing single risk factor-
based guidelines
180,000 (120,000 to 240,000) $7.4 ($5.1 to $9.9)
Absolute risk (≥15%) 67,000 (44,000 to 91,000) $1.3 ($0.9 to $1.8)
Absolute risk (≥10%) 150,000 (97,000 to 200,000) $3.5 ($2.4 to $4.6)
Absolute risk (≥5%)
– including statins
<10%
330,000 (220,000 to 450,000) $10.0 ($7.0 to $14.0
– excluding statins
<10%
290,000 (190,000 to 390,000) $6.5 ($4.5 to $8.6)
Absolute risk (≥5%) assuming the cheaper price of statins in New Zealand
– including statins
<10%
330,000 (220,000 to 450,000) $5.1 ($3.5 to $6.8)
– excluding statins
<10%
290,000 (190,000 to 390,000) $4.7 ($3.3 to $6.3)
NB. All values are rounded to two significant figures. Health gains and costs are pre
median and 95% uncertainty interval. Costs are presented in 2008 Australian dollars
A value of $50,000/QALY is often considered a threshold for cost-effectiveness in Auspending by more efficiently directing preventive drug
therapies to those at greater overall risk. A combination
of blood pressure-lowering drugs for everyone with at
least 5% probability of a cardiovascular event in the next
five years, could save $5.4 billion in health sector costsardiovascular disease prevention in Australia
ion
ent
Lifetime intervention
costs to Patients
($billion)
Lifetime treatment
costs averted
($billion)
Cost-effectiveness*
($/QALY)
$2.6 ($2.6 to $2.6) -$3.4 (−$4.4 to -$2.4) $41,000 ($34,000 to
$52,000)
$3.5 ($2.4 to $4.7) -$2.3 (−$3.4 to -$1.3) $49,000 ($40,000 to
$60,000)
$0.8 ($0.5 to $1.0) -$0.7 (−$1.0 to -$0.4) $21,000 ($17,000 to
$26,000)
$1.9 ($1.3 to $2.6) -$1.5 (−$2.3 to -$0.9) $27,000 ($22,000 to
$32,000)
) $5.5 ($3.8 to $7.4) -$3.7 (−$5.7 to -$2.2) $37,000 ($31,000 to
$44,000)
$4.3 ($2.9 to $5.7) -$3.2 (−$4.8 to -$1.9) $27,000 ($21,000 to
$33,000)
$3.7 ($2.6 to $5.0) -$3.7 (−$5.7 to -$2.2) $16,000 ($12,000 to
$20,000)
$3.6 ($2.5 to $4.8) -$3.2 (−$4.8 to -$1.9) $18,000 ($14,000 to
$24,000)
sented as mean and 95% uncertainty interval, and cost-effectiveness ratio as
. QALY – quality-adjusted life year*.
stralia.
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tion health.
We find that prevention with blood pressure and (low-
price) statin drugs is cost-effective at lower thresholds (5%
five-year risk or approximately 10% ten-year risk) than are
typically recommended for starting drug treatment in
people without existing cardiovascular disease (e.g. 15%
five-year risk in New Zealand [19] or 20% ten-year risk in
the UK [52,53]). Similarly, in Argentina a combination of
statin, diuretic, ACE inihibitor and aspirin was found to be
cost-effective down to at least a 5% ten-year risk of an event
[54] (approximately 10% five-year risk), and in the United
States [55], a combination of statin, ACE inhibitor, beta-
blocker and diuretic when given to men from age 55, was
found to be cost-saving at all levels of risk. Thresholds for
treatment, however, will differ between countries and
change over time, due to variations in disease rates, in
management of risk factors such as smoking, and in the
factors that influence drug prices (e.g. patents) and available
health care budget.
It is important to keep in mind that our estimates of
current use of cardiovascular disease drugs and our cal-
culations of the population proportions that will be eli-
gible, rely on AusDiab data collected in 1999–2000. Not
only is this dataset becoming increasingly dated, it is also
reliant on self-reported use of cardiovascular disease
drugs without specifying the specific drug(s) used. PBS
data suggest an increasing trend in statin prescription,
although trends in general practice (which are more
likely to reflect use in primary prevention) are less ap-
parent [31,32].
A range of other studies have also shown that absolute
risk is a more effective and cost-effective approach to
primary prevention than aiming to reduce blood pressure
and cholesterol below threshold levels [14,56-58]. Our
Australian results concur with the WHO-CHOICE findings
for the WPR A region that includes Australia[14]. Taking
the more recent evidence of drug efficacy into account,
however, as well as the current Australian costs of drugs
and costs of cardiovascular treatment, we would no longer
recommend a combination of statin, diuretic, beta-blocker
and aspirin. The beta-blocker would be better replaced by a
calcium channel blocker and/or ACE inhibitor, both of
which have greater population heath benefits for a similar
level of cost-effectiveness, and recent evidence has cast
doubt on the benefits of aspirin in primary prevention of
cardiovascular disease [59]. New analysis of long-term out-
comes from aspirin prevention trials, however, has found
additional benefits of aspirin in cancer prevention [60], and
further modelling work is now needed to determine if the
health benefits of aspirin will outweigh the bleeding harms,
at a population level, and how these new benefits will influ-
ence its cost-effectiveness if added to the package of drugs
for primary prevention.The role of statins in primary prevention of cardio-
vascular disease in Australia is uncertain; statins have a clear
health benefit (for people at more than 10% absolute risk
[61]), but they are currently an expensive addition to the
prevention package in Australia. The National Health
Amendment (Pharmaceutical Benefits Scheme) Bill 2010
passed by the Senate in November 2010 will guarantee a
16% price reduction for the two most expensive statins
(atorvastatin and rosuvastatin) when they come off patent
around 2012, but this effect is relatively small considering
that Australia currently pays around five times the average
price paid for statins in other OECD countries [62]. There
is potential for the Government to save as much as $7.1
billion over the lifetime of the population, if Australia could
match the much cheaper price of statins in New Zealand.
Conclusion
Changing to an absolute risk-based approach to cardio-
vascular disease prevention in Australia, in line with
other countries such as New Zealand and the United
Kingdom, can save money for the Australian Govern-
ment. A pure absolute risk-based approach will not lead
to substantial changes in the number of Australians eli-
gible for treatment, and the net difference in population
health effects between old and new approaches will not
be substantial, but it could free health dollars that could
be better spent on achieving other health benefits for the
population.
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